CVE-2024-20465

Description

A vulnerability in the access control list (ACL) programming of Cisco IOS Software running on Cisco Industrial Ethernet 4000, 4010, and 5000 Series Switches could allow an unauthenticated, remote attacker to bypass a configured ACL. This vulnerability is due to the incorrect handling of IPv4 ACLs on switched virtual interfaces when an administrator enables and disables Resilient Ethernet Protocol (REP). An attacker could exploit this vulnerability by attempting to send traffic through an affected device. A successful exploit could allow the attacker to bypass an ACL on the affected device.

Category

5.8
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.07%
Vendor Advisory cisco.com
Affected: Cisco IOS
Published at:
Updated at:

References

Link Tags
https://sec.cloudapps.cisco.com/security/center/content/CiscoSecurityAdvisory/cisco-sa-repacl-9eXgnBpD vendor advisory

Frequently Asked Questions

What is the severity of CVE-2024-20465?
CVE-2024-20465 has been scored as a medium severity vulnerability.
How to fix CVE-2024-20465?
To fix CVE-2024-20465, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-20465 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2024-20465 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-20465?
CVE-2024-20465 affects Cisco IOS.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.